CAL
AMED

Capital Analysts LLC’s Amedisys AMED Stock Holding History

Capital Analysts LLC’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-119
Closed -$19K – 934
2021
Q4 		$19K Sell
119
-341
-74% -$54.8K ﹤0.01% 716
2021
Q3 		$69K Hold
460
– – ﹤0.01% 531
2021
Q2 		$113K Hold
460
– – 0.01% 426
2021
Q1 		$122K Buy
+460
New +$130K 0.01% 420

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Capital Analysts LLC's AMED Position: Q1 2022 in Review

Capital Analysts LLC sold out of Amedisys (AMED) in Q1 2022, closing a stake of 119 shares — an estimated $19K sold.

Capital Analysts LLC first reported a position in AMED in Q1 2021 and held it in 4 quarters. The position peaked at $122K in Q1 2021. 328 funds tracked by Wall St. Rank hold AMED as of Q1 2022.

  • Capital Analysts LLC reported no remaining Amedisys position as of Q1 2022 after selling out during the quarter.
  • Capital Analysts LLC sold 119 Amedisys shares in Q1 2022, an estimated $19K.
  • Capital Analysts LLC first reported a position in Amedisys in Q1 2021 and held it in 4 quarters.
  • Capital Analysts LLC's Amedisys position peaked at $122K in Q1 2021.
  • 328 funds tracked by Wall St. Rank held Amedisys as of Q1 2022.

Based on Capital Analysts LLC's 13F filing for Q1 2022, filed 12 May 2022.